These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35723225)

  • 1. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
    Samms RJ; Cheng CC; Fourcaudot M; Heikkinen S; Khattab A; Adams J; Cersosimo E; Triplitt C; Puckett C; Tsintzas K; Adams AC; Abdul-Ghani MA; DeFronzo RA; Norton L
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E123-E132. PubMed ID: 35723225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
    Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
    Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Al-Ozairi E; Jayyousi A
    Diabetes Obes Metab; 2020 Dec; 22(12):2287-2294. PubMed ID: 32729222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
    Yang K; Wang H; Wei R; Xiao W; Tian Q; Wang C; Yang J; Hong T
    Acta Diabetol; 2021 May; 58(5):595-602. PubMed ID: 33452595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
    Seufert J; Urquhart R
    Diabetes Res Clin Pract; 2008 Mar; 79(3):453-60. PubMed ID: 18160120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
    Kress S
    Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
    Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
    Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
    Abdul-Ghani M; Migahid O; Megahed A; Singh R; Kamal D; DeFronzo RA; Jayyousi A
    Diabetes Obes Metab; 2018 Apr; 20(4):1075-1079. PubMed ID: 29227578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.
    Abdelgani S; Puckett C; Adams J; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3497-3504. PubMed ID: 34343296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.